Fluticasone Propionate Chemical Structure (Fp Sal Spl Graphic 01)
Fluticasone Propionate And Salmeterol Powder
Product Images NDC 50090-4214
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Fluticasone Propionate And Salmeterol (NDC 50090-4214). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Salmeterol Xinafoate Chemical Structure (Fp Sal Spl Graphic 02)
Figure 1. Mean Percent Change From Baseline In Fev1 In Subjects With Asthma Previously Treated With Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 03)
This text represents a chart that shows the results of a study on the change in FEV (Forced Expiratory Volume) from baseline levels. The study compares the effects of Fluticasone propionate/salmeterol 100/50 meg twice daily, Fluticasone propionate 100 mog twice daily and Saimeterol 50 mog twice daily on the subjects' FEV levels. The chart shows a 0.5% increase in FEV for the Fluticasone propionate/salmeterol 100/50 meg group, a 0.2% increase for the Fluticasone propionate 100 mog group, and a 0.7% increase for the Saimeterol 50 mog group, all as compared to placebo.*
Figure 2. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 04)
The text presents a graph showing a 9% change in FEV4, with four treatment options labeled: Fluticasone propionate/salmeterol 100/50 mog twice daily, Salmeterol 50 meg twice daily, Fluticasone propionate 100 meg twice daily, and Placebo. The treatments are represented by four lines with different colors. The graph also shows the baseline of the measurement taken on day 1.*
Figure 3. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 05)
This appears to be a chart or graph showing the results of a study comparing the effects of different medications on percent change in FEV (forced expiratory volume) over time. The medications being compared are Fluticasone propionate/salmeterol, Salmeterol, Fluticasone propionate, and a Placebo. The chart shows the data for the study participants over a period of 12 weeks. This chart does not provide enough information to allow for further interpretation or conclusions.*
Figure 4. Predose Fev1: Mean Percent Change From Baseline In Subjects With Chronic Obstructive Pulmonary Disease (Fp Sal Spl Graphic 06)
The text is describing a clinical trial for asthma medication. The trial involved three groups: one group took 38 doses of fluticasone propionate/salmeterol 250/50 mcg twice daily with a baseline forced expiratory volume (FEV) of 1207 mL, another group took salmeterol 50 mcg twice daily with a baseline FEV of 1205 mL, and a third group was given a placebo with a baseline FEV of 1232 mL. The graph shows the change in FEV over time for each group, with the fluticasone propionate/salmeterol group having the greatest improvement in FEV compared to the other two groups.*
Figure 5. Two-hour Postdose Fev1: Mean Percent Changes From Baseline Over Time In Subjects With Chronic Obstructive Pulmonary Disease (Fp Sal Spl Graphic 07)
This is a table displaying the results of a clinical trial comparing the efficacy of two doses of Fluticasone propionate/salmeterol and placebo as a treatment for a respiratory condition. The results are based on the baseline Forced Expiratory Volume (FEV, measured in milliliters) of the participants. The table shows the number of participants (N) and their results at different time points (Day1, Week, and Endpoint) for each treatment group.*
Figure A (Fp Sal Spl Graphic 08)
Figure B (Fp Sal Spl Graphic 09)
Figure C (Fp Sal Spl Graphic 10)
Ifu Figure D (Fp Sal Spl Graphic 11)
Figure E (Fp Sal Spl Graphic 12)
Figure F (Fp Sal Spl Graphic 13)
Ifu Figure G (Fp Sal Spl Graphic 14)
Figure H (Fp Sal Spl Graphic 15)
Label Image (Lbl500904214)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
